<DOC>
	<DOC>NCT02802345</DOC>
	<brief_summary>To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.</brief_summary>
	<brief_title>Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Inclusion criteria: Written informed consent consistent with International Conference on HarmonizationGood Clinical Practice and local laws, signed prior to any study procedures being performed (including any required washout); Male or female patients aged &gt;= 40 years at visit 1; A clinical diagnosis of IPF within the last 6 years before visit 1, based upon the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American thoracic Association 2011 guideline [P1107084]; Combination of highresolution computed tomography (HRCT) pattern, and if available, surgical lung biopsy pattern consistent with a diagnosis of IPF as assessed by the investigator based on a HRCT scan performed within 18 months of visit 1; Carbon Monoxide Diffusion Capacity (corrected for Hb) less or equal to 35% predicted of normal at visit 1. Exclusion criteria: Previous enrolment in this trial; Alanine Transaminase, Aspartate Transaminase &gt; 1.5 fold upper limit of normal (ULN) at visit 1; Total bilirubin &gt; 1.5 fold ULN at visit 1; Relevant airways obstruction (i.e. prebronchodilator Forced Expiratory Volume in 1 second/Forced Vital Capacity &lt;0.7 at visit 1) History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1 Bleeding Risk: Known genetic predisposition to bleeding; Patients who require fibrinolysis, fulldose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin, etc.) or high dose antiplatelet therapy; History of haemorrhagic central nervous system (CNS) event within 12 months prior to visit 1; History of haemoptysis or haematuria, active gastrointestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1; International normalised ratio (INR) &gt; 2 at visit 1; Prothrombin time (PT) and activated partial thromboplastin time (aPTT) &gt; 150% of institutional ULN at visit 1; Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery; History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1; Creatinine clearance &lt; 30 mL/min calculated by CockcroftGault formula at visit 1; Presence of aortic stenosis (AS) per investigator judgement at visit 1; Severe chronic heart failure: defined by left ventricular ejection fraction (EF) &lt; 25% per investigator judgement at visit 1; Presence of idiopathic hypertrophic subaortic stenosis (IHSS) per investigator judgement at visit 1; Seconddegree or thirddegree atrioventricular (AV) block on electrocardiogram (ECG) per investigator judgement at visit 1; Hypotension (systolic blood pressure [SBP] &lt; 100 mm Hg or diastolic blood pressure [DBP] &lt; 50 mm Hg) (symptomatic orthostatic hypotension) at visit 1; Uncontrolled systemic hypertension (SBP &gt; 180 mmHg; or DBP &gt; 100 mmHg) at visit 1; Known penile deformities or conditions (e.g., sickle cell anemia, multiple myeloma, leukemia) that may predispose to priapism; Retinitis pigmentosa; History of vision loss; History of nonarteritic ischemic optic neuropathy; Venoocclusive disease; History of acute IPF exacerbation or respiratory infection within 8 weeks of visit 2. Treatment with nitrates, nacetylcysteine, pirfenidone, azathioprine, cyclophosphamide, cyclosporine, prednisone &gt;15 mg daily or &gt;30 mg every 2 days OR equivalent dose of other oral corticosteroids as well as any investigational drug within 4 weeks of visit 2; Treatment with prostaglandins (e.g., epoprostenol, treprostinil), endothelin1 antagonists (e.g., bosentan, sitaxsentan, ambrisentan), phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, vardenafil) or a stimulator of guanylatcyclase (e.g.,riociguat) within 4 weeks of visit 2; Treatment with potent cytochrome CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir within 4 weeks of visit 2; Supplementation with Larginine and concurrent use of grapefruit juice or St John's wort within 4 weeks of visit 2; Treatment with the reduced dose of nintedanib (100 mg bid) within 4 weeks of visit 2; 27. Permanent discontinuation of nintedanib in the past due to adverse events considered drugrelated; Known hypersensitivity or intolerance to nintedanib, sildenafil, galactose, peanut or soya or any other components of the study medication; A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial; Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment; Further exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>